Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Arcus Biosciences (RCUS) Receivables - Other (2017 - 2025)

Arcus Biosciences has reported Receivables - Other over the past 9 years, most recently at $11.0 million for Q4 2025.

  • Quarterly results put Receivables - Other at $11.0 million for Q4 2025, down 45.0% from a year ago — trailing twelve months through Dec 2025 was $11.0 million (down 45.0% YoY), and the annual figure for FY2025 was $11.0 million, down 45.0%.
  • Receivables - Other for Q4 2025 was $11.0 million at Arcus Biosciences, roughly flat from $11.0 million in the prior quarter.
  • Over the last five years, Receivables - Other for RCUS hit a ceiling of $38.0 million in Q4 2023 and a floor of -$6.0 million in Q1 2023.
  • Median Receivables - Other over the past 5 years was $11.0 million (2025), compared with a mean of $12.6 million.
  • Biggest five-year swings in Receivables - Other: skyrocketed 1573.64% in 2021 and later plummeted 225.0% in 2023.
  • Arcus Biosciences' Receivables - Other stood at $17.3 million in 2021, then dropped by 19.12% to $14.0 million in 2022, then skyrocketed by 171.16% to $38.0 million in 2023, then crashed by 47.37% to $20.0 million in 2024, then crashed by 45.0% to $11.0 million in 2025.
  • The last three reported values for Receivables - Other were $11.0 million (Q4 2025), $11.0 million (Q3 2025), and $15.0 million (Q2 2025) per Business Quant data.